Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
The Best Dividend Stocks to Buy With $5,000 in November
02.11.2026 17:35
AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
02.11.2026 16:22
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
How well is J&J’s incubator model working?
02.11.2026 14:28
After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more targeted approach to new science.
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever
02.11.2026 13:47
Healthcare bills arrive whether the economy cooperates or not, and two S&P 500 drugmakers have quietly turned that reality into decades of unbroken dividend raises. The question is whether their cash flow holds up under the pressures now building against each one.
3 Best Dividend Stocks for a $100,000 Passive Income Strategy
02.11.2026 13:02
Retirees who sell shares to cover monthly bills hand the market a weapon to use against them, but three dividend stocks offer a different path where the portfolio pays you without shrinking.
Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle
02.11.2026 12:59
Key Stats for Johnson & Johnson StockCurrent Price: $273. 20Target Price (Mid): ~$342Street Target: ~$279Potential Total Return: ~25%Annualized IRR: ~5.
ETFs Are Buying Johnson & Johnson (JNJ) on Oct. 29
02.11.2026 11:01
ETFs bought $35.1 million of Johnson & Johnson stock on Oct. 29.
J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3
02.11.2026 10:51
Real-world and observational findings from 1,379 patients across US and European centres reported decreased mortality than the CHIP-BCIS3 trial.
What Is Johnson & Johnson (JNJ) Signaling With Its New Impella Heart Pump Data?
02.11.2026 09:08
Johnson & Johnson (NYSE:JNJ) reported positive real-world outcomes for its Impella heart pumps at the TCT 2026 meeting on 2 November 2026. Registry data from U.S. and European hospitals showed Impella use in high-risk percutaneous coronary intervention with mortality rates below prior study levels. Clinicians also reviewed ongoing PROTECT IV trial progress, which is expected to add further evidence on Impella-supported high-risk coronary procedures. The new Impella real-world results matter,...
Johnson & Johnson: A Quality Healthcare Giant, Fairly Priced For Growth
02.11.2026 02:52
Johnson & Johnson's Innovative Medicine segment outperforms, driven by Darzalex, Tremfya, and promising pipeline drugs. See why I rate JNJ stock a Hold.
3 Biotech Stocks With Upside Of Up To 80%
31.10.2026 04:21
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article walks through three such biotech stocks screened for balance sheet strength and valuation discipline. The three highlighted biotech stocks are only a sample of what screens well on balance sheet...
Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference
30.10.2026 15:47
Two health care ETFs track the same sector but own very different slices of it, and for retirees building a portfolio, that gap in biotech exposure and concentration could matter more than the nearly identical returns suggest.
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
30.10.2026 13:23
J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
30.10.2026 12:36
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
CFOs On the Move: Week ending Oct. 30
30.10.2026 12:01
Goodyear hires a new finance chief, Norwegian Cruise Line names an insider as chief financial officer and Etsy starts its search for a new CFO.
Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First
30.10.2026 07:30
Nanobiotix stock hinges on J&Jâs JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX.
Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings
29.10.2026 03:40
Johnson & Johnson's Q3 results showed the strength of the pharma business. Click here to read more about JNJ stock and why it is rated a Hold.
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
28.10.2026 17:21
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
28.10.2026 14:45
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
Why JEPI’s Total Return Has Outpaced Its Payout
28.10.2026 13:05
JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that split reveals something most income investors never check before buying a covered-call fund.